One of Dr. Giubellino's chief interests has been the investigation and development of biomarkers for cancer diagnosis, as well as for prognostic and predictive purposes. He has contributed to defining the proto-oncogene MET, the tyrosine kinase receptor for the hepatocyte growth factor (HGF), as a cancer biomarker. Given the concurrent role of MET in the modulation of the immune response and the interplay with immune checkpoints in other malignancies, He investigated the expression pattern of MET and the immune checkpoint PD-L1, a relevant target for immunotherapy. More recently, he has been involved in several studies using the relatively new technology of Spatial Transcriptomics and Spatial Proteomics, techniques that allow the precise localization of multiple mRNAs and proteins in a morphologic context in tissue samples. Hia research group is exploring the use of digital pathology and artificial intelligence to enhance diagnostic and prognostic evaluation of clinical tissue samples. Giubellino thinks this comprehensive approach will reveal relevant biomarkers to help clinicians to improve the life and management of patients visiting our Clinics and Health System.
